A case–control study to evaluate the risk of agranulocytosis and neutropenia associated with the concomitant use of metamizole and fluoropyrimidine and oxaliplatin-based chemotherapy

Study identification

• EU PAS number:
  EUPAS1000000933
• Study ID:
  1000000933
• Official title and acronym:
  A case–control study to evaluate the risk of agranulocytosis and neutropenia associated with the concomitant use of metamizole and fluoropyrimidine and oxaliplatin-based chemotherapy
• DARWIN EU® study:
  No
• Study countries:
  Spain
• Study description:
  This is an observational, retrospective, multicentre case–control study. All necessary information will be collected from the electronic health records of patients treated with fluoropyrimidines and oxaliplatin.; The study will include patients diagnosed with different neoplasms who have received chemotherapy with fluoropyrimidines and oxaliplatin, prescribed by medical oncology services.
• Study status:
  Ongoing

Research institutions and networks

Institutions

Puerta de Hierro-Majadahonda University Hospital

Study timelines

Date when funding contract was signed

Planned:09/02/2026

Actual:09/02/2026

Study start date

Planned:02/02/2026

Actual:10/02/2026

Date of final study report

Planned:30/09/2026

Sources of funding

No external funding

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable